Why this market is different

The Sales Academy's specialism module: how selling actually works in UK life sciences and health technology, written for readers with no commercial experience. Everything here is at the level of durable structure — names of bodies, routes and standards change; before any interview, spend 20 minutes confirming the current state of anything you plan to cite.

What you'll learn

• Why healthcare and life-science selling is structurally different from ordinary B2B software sales — and why that difference favours the prepared.
• A working map of the NHS as a customer: the organisations, who holds money, and who sits around the table in a real deal.
• The procurement routes (frameworks, tenders, direct awards) and compliance gates (DTAC, DSPT, DCB0129/0160, UKCA/CE) every NHS-facing seller must discuss fluently.
• The evidence ladder healthtech deals climb, why pilots stall, and what makes them convert.
• How pharma/biotech selling differs: the R&D organisation, GxP and validation, and what CDMO/CRO business development actually involves.
• The distinct worlds of lab consumables/instrument sales and pharma field sales — enough to hold your own in interviews for territory account-management and therapy-specialist roles.
• How to build domain credibility without sector experience — the kinds of assets that work, and how to wield them without overclaiming.

1. Why this market is different

In generic B2B software sales, a deal cycle (first conversation to signed contract) might run one to three months, one director can sign off, and the worst outcome of a bad purchase is wasted budget. Healthcare and life sciences differ on every axis:

Long cycles. Six to twenty-four months from first meeting to contract is normal. Nothing is wrong when a deal takes a year; something is wrong when a seller plans as if it will take a quarter. So your pipeline (the set of open opportunities you are working, tracked in a CRM — customer relationship management software) needs many overlapping deals at different stages, with progress measured by verifiable exit criteria (a named budget line, a completed governance review), not meetings held.

Committee buying. There is almost never a single economic buyer (the person with authority to release the money). Decisions pass through clinical, technical, information governance, procurement and finance hands. Your job is less "convince one person" and more "help one motivated insider build a case that survives every committee it passes through".

Evidence requirements. Healthcare buyers want evidence proportionate to clinical risk — case studies at minimum, peer-reviewed studies and health-economic analyses for anything touching patient care. Section 5 covers the ladder.

Risk aversion — for good reasons. A hospital that buys bad software can harm patients and end up in the press. Sellers who treat caution as an obstacle lose; sellers who arrive with the safety case half-built win.

Regulated products. Software that makes or informs clinical decisions may legally be a medical device, with registration, classification and marking requirements (section 4). "Is this a medical device, and what class?" must be answerable about anything you sell.

Budget cycles. The NHS financial year runs April to March. Budgets are set before April; unspent money can surface late in the year (roughly January–March), but big new commitments are hardest to land mid-year with no budget line. Good NHS sellers work backwards from April: influence business planning in autumn, be "in the plan" by spring.

Field note

Do the runway maths from the vendor's side: a 14-month procurement against an 18-month funding runway means a startup can win the deal and still run out of cash before the first invoice is paid. This is why NHS-facing companies obsess over payment terms and cash collection, why "we're in procurement" is not the same as "we're safe", and why experienced sellers qualify brutally before spending a year on a maybe. It also explains some odd competitor behaviour — aggressive year-end discounting is often about survival, not strategy.

None of this makes the market slower-witted than tech — it makes it legible: rules published, committees named, frameworks searchable. The seller who does the homework has a genuine edge — and unlike experience, homework is available to a newcomer from day one. That idea runs through the whole module and comes to a head in section 9.

2. The NHS: a map of the buyer

"Selling to the NHS" is a category error — the NHS is hundreds of legally separate organisations inside a shifting national structure. The durable pieces (England-centric; Scotland, Wales and Northern Ireland run their own systems):

NHS trusts

NHS trusts are the operating units of secondary care — hospitals, mental health, community and ambulance services; on the order of two hundred in England, each a legal entity with its own board, budget and procurement function (foundation trusts have more financial autonomy).

Commercial relevance: the trust is usually your actual customer — the entity that signs, deploys and pays.

Primary care

Primary care means GP practices (plus pharmacy, dental, optometry). GP practices are mostly small independent businesses contracted to the NHS, grouped into Primary Care Networks (PCNs).

Selling here is a higher-volume, lower-ticket motion — closer to SMB sales, often channelled through federations, PCNs or ICB-level deals. (Several of the UK's fastest-growing healthtech companies sell here: thousands of practices, fast cycles by NHS standards.)

Integrated Care Systems (ICSs)

Integrated Care Systems (ICSs) are regional partnerships planning health and care for a geography; each has an Integrated Care Board (ICB), the statutory NHS body holding and allocating the NHS budget for its area and commissioning services. There were 42; mergers began in April 2026 and the number is falling — check the current map before an interview.

Commercial relevance: ICBs matter when your value case spans organisations (community wound care, waiting lists, virtual wards) or funding is regional; trusts matter when value lands inside one hospital. Many digital deals involve both.

NHS England

NHS England has been the national management body — strategy, national programmes, digital standards. In March 2025 the government announced its abolition, with functions absorbed into the Department of Health and Social Care (DHSC); legislation was going through Parliament in 2026.

Commercial relevance: national bodies set the rules of the game (standards, frameworks, national funding programmes) but rarely buy your product. The exact org chart is volatile; "national centre sets standards, local organisations buy" is durable.

Voice from the field

"There are plenty of clinicians, charities, start-ups and NHS trusts that can do a much better job of designing new services than we can at the centre."
— Matthew Gould, then CEO of NHSX, diginomica (2019)

NICE

NICE — the National Institute for Health and Care Excellence — judges whether treatments and technologies are clinically and cost effective, and publishes guidance. For digital health it maintains an Evidence Standards Framework describing what evidence a technology of a given risk level should have, plus early-value assessment routes for promising medtech.

Commercial relevance: NICE rarely buys anything, but positive guidance is a powerful door-opener, and its framework tells you what buyers will ask for.

MHRA

MHRA — the Medicines and Healthcare products Regulatory Agency — is the UK regulator for medicines and medical devices, including software and AI as a medical device.

Commercial relevance: it determines whether your product is a regulated device and what class, driving registration, marking and much of the evidence expectation. A clinical-AI seller who cannot state their product's regulatory status will be found out in the first serious meeting.

Who holds budget?

• Trusts hold operational budgets — with internal splits (nursing, an imaging directorate, IT) and a capital (assets) vs revenue (recurring costs like SaaS) distinction that can decide which pot your deal fits.
• ICBs hold commissioning budgets and often digital transformation funds.
• National programmes occasionally fund specific technology categories — these come and go; watching the public procurement record (section 4) is how you spot what is actually being funded rather than what is merely announced.